Brunt, A. Murray External Entity

Publications

Sort by

Selected publications

  • 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.  Lancet2013 Academic Article GET IT
    Times cited: 175

Other